Persistent forms of synaptic plasticity are widely thought to require the synthesis of new 43
Introduction 65
The importance of protein synthesis in synaptic plasticity was first demonstrated 66 in the rodent hippocampus in the dentate gyrus of behaving rats (Krug et al. 1984) and 67
Drug preincubation was performed at room temperature in submersion maintenance 158 chambers containing ACSF saturated with 95% O 2 /5% CO 2 . All drugs were prepared as 159 stock solutions in DMSO and then added to ACSF. 4EGI-1 final vehicle concentration: 160 1% DMSO, 0.5% β-cyclodextrin (Sigma); hippuristanol final vehicle concentration: 1% 161 DMSO. Drugs were applied for 60 min before HFS and for various times following the 162 HFS as shown in the figure (20-40 minutes after HFS, as indicated). 163
164

Isolation of NMDA receptor-mediated fEPSPs. 165
Baseline fEPSPs were collected as described above. After establishing a stable 166 baseline, slices were incubated in either vehicle or 4EGI-1 (100 µM) for 60 minutes. 167
Then, ACSF containing 0 mM MgCl 2 and 4 mM CaCl 2 was applied to treated slices to 168 evoke mixed AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) and NMDA 169 receptor-mediated fEPSPs. CNQX (6-cyano-2,3-dihydroxy-7-nitro-quinoxaline) at 20 μM 170 then was applied to slices to isolate NMDA receptor-mediated fEPSPs. Confirmation 171 that the remaining fEPSP was mediated by NMDA receptors was obtained with a final 172 application of 100 μM APV to the slices. 173
174
Immunoprecipitation 175
Tissue was homogenized in ice-cold lysis immunoprecipitation buffer as previously 176 described (Hoeffer et al. 2011 ). Cleared hippocampal homogenate (150-250 μg) was 177 incubated with anti-eIF4G (1:100) (Bethyl Laboratories) and gently shaken overnight at 178 4°C. The antibody/lysate mix was incubated with 75 μL IgG bound to agarose-beads 179 (Pierce). The bead/sample slurry was incubated through rocking at 25°C for two hours 180 (or 4°C overnight). Supernatant was removed and saved, and immunoprecipitates were 181 washed three times in lysis buffer, and once in wash buffer in mM (50 HEPES pH 7.5, 182 40 NaCl, 2 EDTA) before resolution with Western blots. 183
184
Puromycin Protein Labeling 185
Hippocampal slices were prepared as described above (Hoeffer et al. 2008 ). Slices then 186
were subjected to the pharmacological pretreatment (cycloheximide, 4EGI-1, 187 hippuristanol) for 60 min at the desired concentration. Proteins were labeled using an 188 adaption of the SuNSET protocol (Hoeffer et al. 2011; Schmidt et al. 2009 ). At the end 189 of the protein synthesis inhibitor incubation, puromycin (10 μg/mL in vehicle) was added 190 and slices were further incubated for 60 min. During this incubation time, newly 191 synthesized proteins were end-labeled with puromycin. Slices were transferred to 192 oxygenated ACSF in three successive washes of two minutes then were flash-frozen on 193 dry ice. Area CA1 was microdissected from slices and protein lysates were prepared 194 and blotted. Puromycin-labeled proteins were identified on blots using the mouse 195 monoclonal antibody 12D10 (1:5,000 from a 5-mg/mL stock). Because only a small 196 fraction of the brain proteins were labeled, signal from blots was identified using ECL-197
Advance. Protein synthesis levels were determined by taking the total lane signal from labeled protein) that were resolved on Novex precast 4 to 12% gradient gels 210 (Invitrogen), transferred to a PVDF membrane, and processed for overnight incubation 211 with primary antibodies (see below) followed by secondary antibodies. Membranes were 212 washed and proteins were detected with enhanced chemiluminescence reagent (ECL+; 213 GE Healthcare) and visualized using a Kodak 4000MM or GE LAS4000 imager to 214 obtain pixel density values for the band of interest. All images were obtained using 215 maximum sensitivity settings with no binning (0-65 K signal range). No images analyzed 216 presented saturating signals for the bands of interest (>65 K grayscale value). Band 217 density values were normalized to one of the following: β-actin, GAPDH, or eIF4G 218 (eIF4G for immunoprecipitation experiments). All gels included loading controls of 219 known concentration to allow comparisons across different blots. 220
221
Antibodies 222
The following antibodies were used in this study: eIF4E monoclonal mouse antibody 223
(1:1000; Abgent), eIF4G1 polyclonal rabbit antibody (1:100; Bethyl laboratories), 224 eIF4G1 polyclonal mouse antibody (1:1000; R&D Systems), GAPDH rabbit polyclonal 225 antibody (1:1000; Chemicon), and puromycin monoclonal antibody (mouse 12 D 10, 226 1:5000). For information about the puromcyin monoclonal antibody, see (Schmidt et al. 227 2009). Secondary antibodies used: goat anti-rabbit IgG-HRP (1:10,000; Promega) and 228 goat anti-mouse IgG-HRP (1:10,000; Promega). 229
230
Data analysis 231
Data are presented as mean ± SEM. Statistics was performed using GraphPad software 232 concentrations of 4EGI-1 also reducing eIF4F formation but not to the same levels as 253 with 100 µM (data not shown). We proceeded to examine basal synaptic transmission, 254 as measured by synaptic output in response to a stimulatory input in hippocampal slices 255 treated with 4EGI-1. We found that input/output curves were indistinguishable between 256 slices treated with 4EGI-1 and vehicle ( Figure 1B) . We next examined whether 4EG1-1 257 exposure was neurotoxic when applied for extended periods of time. When slices were 258 exposed to 50 or 100 µM 4EGI-1 we did not observe a significant reduction in basal field 259 excitatory field potentials (fEPSP) ( Figure 1C 
PPF 293
In addition to mRNA cap-binding via eIF4E, the eIF4F complex also contains 294 eIF4A, an RNA helicase critical for cap-dependent translation (Raught et al. 2000) . To 295 investigate the role of eIF4A in protein synthesis-dependent LTP, we used hippuristanol 296 (Bordeleau et al. 2006) to block eIF4A activity in the hippocampus. We first examined 297 basal synaptic transmission and ound that input/output curves were indistinguishable 298 between slices treated with hippuristanol (10 μM) and vehicle ( Figure 3A ). In addition, 299 when slices were exposed to 10 μM hippuristanol for 60 minutes there was no 300 significant alteration in fEPSPs ( Figure 3B ). Finally, PPF was similar in hippuristanol-301 treated slices and vehicle-treated slices at several interpulse intervals ( Figure 3C ). 302
Taken together these findings indicate that inhibiting eIF4A activity with hippuristanol 303 does not affect either basal synaptic transmission or presynaptic calcium release 304 properties in area CA1 of hippocampal slices. 305 306 eIF4F-mediated RNA helicase activity is required for protein synthesis-dependent 307
LTP 308
Because inhibition of eIF4A activity did not affect either basal synaptic 309 transmission or presynaptic facilitation, we next tested whether eIF4A activity was 310 vehicle or eIF4F inhibitors. We found that pre-incubation of slices with either 4EGI-1 or 337 hippuristanol blocked protein synthesis ( Figure 5A ). We also observed that neither 338 4EGI-1 nor hippuristanol blocked protein synthesis as effectively as cycloheximide, a 339 general protein synthesis inhibitor ( Figure 5A ). We next asked whether induction of L-340 LTP was correlated with increased protein synthesis and if so, whether eIF4F was 341 required for the increase. We again incubated hippocampal slices with the inhibitors of 342 Figure 5B. Using four trains of HFS to induce L-LTP we observed a significant increase 345 in newly synthesized proteins compared to control slices ( Figure 5C ). We also observed 346 that both 4EGI-1 and hippuristanol attenuated the L-LTP-associated increase in protein 347 synthesis ( Figure 5C ). These data provide evidence that multiple components of eIF4F 348 are involved in the synthesis of new proteins in response to stimulation that induces 349 protein synthesis-dependent LTP. However, at least one study using similar approaches to examine L-LTP in the dentate 395 gyrus in vivo did not identify a role for mTORC1 in the regulation of eIF4F (Panja et al. 396 2009). In addition, a recent study casted doubt on the phospho-regulation of 4E-BP2, 397
suggesting that protein synthesis-dependent synaptic plasticity in the brain utilizes a 398 mechanism independent of mTORC1 phosphorylation of 4E-BP2 and thus eIF4F 399 experiments it is likely that eIF4A bound to eIF4G is the critical target of hippuristanol 414 blockade because its affinity for eIF4A as part of the eIF4F complex is much greater 415 than that eIF4A in its free form (Oberer et al. 2005 ) and it was shown previously that 416 hippuristanol is a potent inhibitor of eIF4A activity in the eIF4F complex (Bordeleau et al. 
